Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Invitrall

Invitrall develops advanced diseases in vitro models that represent human genetic diversity that provides innovative solutions.
2024
1-10
1-10
Curitiba, Parana, Brazil

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

$250.0K

Last Funding Amount

$250.0K

Last Funding Date

01-07-2024

Startup Stage

Pre-Seed

Lead Investors

GRID EXPONENTIAL

About

Over 90% of drugs fail in clinical trials, largely due to the limited representativeness of pre-clinical models. Traditional models—whether animal or in vitro—fail to effectively capture humans’ complexity and genetic diversity. At Invitrall, we are overcoming this challenge. We develop advanced diseases in vitro models that represent human genetic diversity, providing innovative solutions to test the safety and efficacy of pharmaceutical and cosmetic products. Our technology bridges the gap left by traditional experimental models, helping to accelerate the development of therapies for various diseases.

Something missing or incorrect on this page? Help us enrich this information